A six-week study found that patients taking ADDERALL XR showed significant improvements in driving performance and cognitive functioning compared to placebo. The medication reduced ADHD symptoms by 30% in 80% of patients, leading to better driving skills and safety.
Researchers found that extended-release carbamazepine capsules improved symptoms in patients with bipolar disorder, including those experiencing mania and mixed episodes. The treatment was generally well-tolerated, with few adverse events reported.
Elevated Lp-PLA2 levels are associated with a significantly increased risk of ischemic stroke, even after accounting for traditional cardiovascular risk factors. The enzyme's potential as an independent diagnostic measure is being evaluated.
A large study reveals that co-administration of Zetia and fenofibrate significantly lowers LDL cholesterol, non-HDL cholesterol, and apo B to a greater extent than fenofibrate alone in mixed hyperlipidemia patients. This improvement is also seen in HDL cholesterol levels.
FOSRENOL effectively controls hyperphosphatemia, a leading cause of renal osteodystrophy and bone pain in ESRD patients. Long-term use maintains bone health status without worsening bone status, unlike aluminum-based phosphate binders.
In a subgroup of high-risk patients, VYTORIN significantly reduced LDL cholesterol by 59% compared to Lipitor. This resulted in more patients achieving an LDL cholesterol goal of less than 100mg/dL with VYTORIN, and increased HDL cholesterol levels.
A Phase 2 trial showed AMG 162 increased bone mineral density at the hip, spine, and total body by 4-7% compared to FOSAMAX®. The therapy was well-tolerated with a common adverse event of dyspepsia.
Two landmark studies show that Taxotere-based regimens improve patients' PSA responses by 43% and pain responses by 59%, leading to a 27% increase in disease-progression-free survival. The treatment also provides hope to thousands of men worldwide, offering an important new option for living longer.
A multicenter trial demonstrated that Taxotere in combination with cisplatin and 5-FU prolonged progression-free survival by 12.7 months compared to the standard treatment. Patients also showed significantly improved overall response rates, indicating a potential new paradigm for treating head and neck cancer.
A study led by Russell G. Postier found that tigecycline produced a 74 percent cure rate for hospitalized patients with complicated skin and skin structure infections (cSSSI), demonstrating promising efficacy against a wide spectrum of bacteria. The antibiotic's safety profile was also acceptable.
A phase III study presented at the American Psychiatric Association Meeting found that ADDERALL XR improves ADHD symptoms for up to 24 months. The medication reduced symptoms by an average of 45% in patients who received it consistently, with a significant reduction in inattention and impulsivity subscales.
A survey of adults reveals long-term consequences of ADHD, including lower educational achievement, relationship instability, and higher rates of stress, depression, and substance abuse. Adults with ADHD are also more likely to experience negative self-image and engage in harmful behaviors.
A new study shows that mixed amphetamine salts significantly improve behavior scores compared to atomoxetine, particularly in a 12-hour analog classroom setting. Additionally, mixed amphetamine salts also improve attention and academic productivity, allowing children to complete more math problems correctly.
Researchers have identified a set of six genes that correlate with survival in diffuse large B-cell lymphoma, including LMO2, BCL6, and CCND2. The findings suggest that molecular profiling may help refine prognoses for this difficult-to-treat blood cancer.
A new study on virtual colonoscopy has shown remarkable improvement in diagnosis but also revealed significant discomfort for patients. Gastrointestinal specialists emphasize the need for verification of results and caution against relying solely on virtual colonoscopy.
A 11-week study showed lanthanum carbonate significantly reduced serum phosphorus levels in hemodialysis patients, meeting the new K/DOQI guidelines. Sixty percent of patients achieved target levels, with lower calcium x phosphate product.
A study of 177 patients found higher blood levels of sitosterol were associated with an increased risk of coronary events. Patients with high LDL cholesterol and elevated sitosterol levels were at nearly double the risk of a major coronary event.
A study published in the New England Journal of Medicine found that everolimus significantly reduced the incidence of acute rejection and cardiac allograft vasculopathy in heart transplant patients. The medication also lowered rates of cytomegalovirus infection, a major risk factor for these complications.
Eighty percent of patients treated with combination therapy experienced no radiographic progression, compared to 68% on ENBREL alone and 57% on methotrexate. Combination therapy and ENBREL monotherapy provided significant inhibition of joint damage.
In a global, double-blind, placebo-controlled study, ENBREL demonstrated significant improvements in Psoriasis Area and Severity Index (PASI 75) scores after 12 weeks of treatment. Nearly half of patients treated with 50mg or 25mg of ENBREL twice weekly achieved PASI 75 versus 3% of placebo-treated patients.
In a multi-center, double-blind study, ENBREL 50 mg administered once weekly achieved an ACR 20 response in 50% of patients, compared to 19% in the placebo group. ENBREL also showed comparable improvement in HAQ and patient-reported measures of global status and pain.
A Phase 3 study showed ENBREL significantly improved back pain, mobility, and function in patients with ankylosing spondylitis. At 12 weeks, 60% of patients achieved a 20% improvement, while at 24 weeks, 58% did so.
Long-term data show effective control of serum phosphate levels, with 71.7% achieving target levels after one year and 68.9% after three years. Low incidence of hypercalcaemia is also maintained throughout the study period.
A clinical trial with over 2,900 patients found that once-daily Adderall XR significantly improved children's quality of life and reduced ADHD symptoms. The study used the PedsQL instrument to assess four health dimensions: physical, emotional, social, and school functioning.
A two-year study found significant improvements in ADHD symptoms in children treated with once-daily Adderall XR, with at least 35% sustained improvement. The medication remained effective in controlling symptoms over an extended period.
Effexor/Effexor XR demonstrated higher remission rates (41%) compared to SSRIs (35%), while also resolving physical symptoms of depression. The analysis included over 7,000 patients across 30 head-to-head studies.
A 12-month study comparing FOSRENOL and calcium carbonate found that FOSRENOL led to a 'considerably better outcome' on bone histology, with halved rates of patients with osteomalacia, adynamic bone disease, or hyperparathyroidism. This contrasts with the calcium carbonate group, which showed an increase in these conditions.
A 52-week extension trial found that lanthanum carbonate successfully maintained lowered phosphate levels in patients with end-stage kidney disease. The study demonstrated a good safety profile, with no treatment-related serious adverse events, and supported the use of Fosrenol as a long-term treatment option.
A landmark analysis found that oxycodone was involved in only a small percentage of drug abuse deaths, with multiple drugs present in most cases. The study suggests that abusing opioids with other substances increases risk and calls for enhanced classification methods.
Acorda Therapeutics has received a Phase 2 grant from the National Institutes of Health (NIH) to develop a new treatment approach for multiple sclerosis (MS). The company's antibodies, sHIgM22 and sHIgM46, have shown promise in stimulating myelin regrowth in animal models.
Acorda Therapeutics has received the L.W. Freeman Award for its pioneering work in regenerative therapies and functional improvements for spinal cord injury patients. The company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and aims to restore function in people with SCI.
Lantern carbonate has been shown to reduce high phosphate levels and calcium levels in the blood, reducing the risk of calcification of the coronary arteries. The study also found that lanthanum carbonate is well-tolerated and associated with a lower incidence of serious adverse events.
A clinical trial found that consuming almonds daily significantly reduces LDL cholesterol levels in hyperlipidemic subjects. The study also showed that eating more almonds increased the reduction of 'bad' cholesterol even further, without resulting in weight gain.
The InnoLet system features a dosing dial and reversible dose mechanism, making it easier for patients to administer accurate doses. Clinical studies show that 95% of participants rated the device as 'very easy' or 'easy' to use.
Fampridine-SR shows promise in reducing spasticity and improving bladder, bowel, and sexual function in patients with chronic SCI. The Phase 3 trial enrolls 360 patients at leading clinical centers in the US and Canada.
Researchers conducted two studies on venlafaxine XR, a SNRI medication, for social anxiety disorder (SAD) treatment. The results showed significant reductions in SAD symptoms as early as four or six weeks after treatment began, with continued improvements through week 12.
The company's phase I clinical trial will examine NicVAX's safety and ability to stimulate the immune system in nonsmokers. If successful, additional trials will be conducted to investigate its efficacy in smokers and ex-smokers.
The Q TRAP system combines triple quadrupole and ion trap mass spectrometry, enabling researchers to identify more proteins and metabolites with higher confidence and accuracy. This new technology is expected to increase productivity in drug discovery through improved metabolite identification.
A six-week study of 246 black men found that Viagra significantly improved erections and sexual intercourse ability compared to placebo. ED was a common problem among black men, affecting 24% of those aged 40 and above. Treatment with Viagra was well-tolerated, with no serious adverse effects observed.
A nationwide study of over 1,500 Hispanic, white, and black men found that erectile dysfunction (ED) affects approximately 20% of Hispanic men, 22% of whites, and 24% of blacks. The study also revealed a strong link between ED and cardiovascular disease, as well as diabetes.
A recent study found that venlafaxine is effective in reducing symptoms of GAD in children and teens, with a significant decrease of 18.6 points on a standard measurement scale. The medication showed promising results in improving symptoms, with 64% of participants responding to therapy.
The BAXJECT device eliminates filter needles during Factor VIII concentrate infusion preparation, reducing risk of needle-stick injury and contamination. The device is designed for safe and easy use by children and adults alike.
In a study involving 495 patients, Effexor XR showed significantly higher remission rates compared to placebo. At the end of 12 months, 67% of patients maintained remission after a year of therapy, with 46% on placebo.
Baxter's rAHF/PFM therapy has shown bioequivalence with Recombinate, a current gold-standard, indicating comparable hemostatic efficacy in managing Haemophilia A. This new method reduces theoretical risk of disease transmission by eliminating human or animal-derived raw materials.
Most Americans are getting less than the recommended daily intake of vitamin E, with almonds being a concentrated source of this essential nutrient. Almonds deliver more nutrition per calorie compared to other snack foods.
A 12-week study found that Viagra improved erections for 71% of men, compared to 18% on placebo. The medication was well-tolerated with mild side effects, making it a good option for men who need to treat both high blood pressure and erectile dysfunction.
A mobile screening program at 39 Winston Cup race weekends screened 24,000 people, revealing high blood pressure and cholesterol levels as risk factors for heart disease. The screenings also assessed erectile dysfunction and provided health information and advice to participants.
A recent study found that smoking cessation success rates are equally good with over-the-counter (OTC) or prescription nicotine replacement therapy (NRT). OTC NRT had higher abstinence rates at six weeks and six months compared to prescription NRT. The study suggests that removing the prescription status of NRT products may promote saf...
Six studies presented at the 2002 Experimental Biology conference support almonds' role in lowering 'bad' cholesterol and protecting against cell damage. Eating a handful of almonds daily may significantly reduce total and LDL cholesterol levels, and even lower risk of heart disease by up to 10%.
A retrospective study of 1407 VNS Therapy patients found that reducing antiepileptic medications did not impair seizure control. The study analyzed changes in medication use and seizure rates over one year, with no significant differences between groups.